Search

Your search keyword '"Adamson, John W."' showing total 335 results
Start Over Author "Adamson, John W."
335 results on '"Adamson, John W."'

1. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Author

Macdougall, Iain C, Bircher, Andreas J, Eckardt, Kai-Uwe, Obrador, Gregorio T, Pollock, Carol A, Stenvinkel, Peter, Swinkels, Dorine W, Wanner, Christoph, Weiss, Günter, Chertow, Glenn M, Participants, Conference, Adamson, John W, Akizawa, Tadao, Anker, Stefan D, Auerbach, Michael, Bárány, Peter, Besarab, Anatole, Bhandari, Sunil, Cabantchik, Ioav, Collins, Alan J, Coyne, Daniel W, de Francisco, Ángel LM, Fishbane, Steven, Gaillard, Carlo AJM, Ganz, Tomas, Goldsmith, David J, Hershko, Chaim, Jankowska, Ewa A, Johansen, Kirsten L, Kalantar-Zadeh, Kamyar, Kalra, Philip A, Kasiske, Bertram L, Locatelli, Francesco, Małyszko, Jolanta, Mayer, Gert, McMahon, Lawrence P, Mikhail, Ashraf, Nemeth, Elizabeta, Pai, Amy Barton, Parfrey, Patrick S, Pecoits-Filho, Roberto, Roger, Simon D, Rostoker, Guy, Rottembourg, Jacques, Singh, Ajay K, Slotki, Itzchak, Spinowitz, Bruce S, Tarng, Der-Cherng, Tentori, Francesca, Toblli, Jorge E, Tsukamoto, Yusuke, Vaziri, Nosratola D, Winkelmayer, Wolfgang C, Wheeler, David C, and Zakharova, Elena

Subjects
Hematology, Digestive Diseases, Nutrition, Kidney Disease, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Cardiovascular Diseases, Ferritins, Hematinics, Hemoglobins, Hepcidins, Humans, Hypersensitivity, Infections, Iron, Iron Deficiencies, Iron Overload, Oxidative Stress, Renal Insufficiency, Chronic, chronic kidney disease, hypersensitivity, infections, iron, overload, oxidative stress, Conference Participants, Clinical Sciences, Urology & Nephrology
Abstract

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

Published
2016

2. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

3. Design and Chemical Synthesis of a Homogeneous Polymer-Modified Erythropoiesis Protein

Author

Kochendoerfer, Gerd G., Chen, Shiah-Yun, Mao, Feng, Cressman, Sonya, Traviglia, Stacey, Shao, Haiyan, Hunter, Christie L., Low, Donald W., Cagle, E. Neil, Carnevali, Maia, Gueriguian, Vincent, Keogh, Peter J., Porter, Heather, Stratton, Stephen M., Wiedeke, M. Con, Wilken, Jill, Tang, Jie, Levy, Jay J., Miranda, Les P., Crnogorac, Milan M., Kalbag, Suresh, Botti, Paolo, Schindler-Horvat, Janice, Savatski, Laura, Adamson, John W., Kung, Ada, and Bradburne, James A.

Published
2003

37. Regulation of red blood cell production

Author

Adamson, John W.

Subjects
Erythropoietin -- Physiological aspects, Anemia -- Care and treatment, Erythrocytes -- Physiological aspects, Health, Health care industry
Abstract

Erythropoietin, which is produced by peritubular capillary lining cells of the kidney, is critical to the production of red blood cells. Endogenously produced erythropoietin circulates in the plasma to act on specific target cells in the marrow through cell surface receptors. The primary target of erythropoietin action is the erythroid colony-forming cell. in addition to proliferative effects, high circulating erythropoietin levels result in the premature release of marrow reticulocytes and the mobilization of marrow progenitor cells. Production of endogenous erythropoietin increases in response to the stress of anemia or hypoxemia. iron, an important element in hemoglobin synthesis, is bound to the iron transport protein transferrin, and the complex is internalized, along with the transferrin receptor, by the developing erythroid cell. Within the cell, the iron molecule is subsequently split off and either used for hemoglobin synthesis or stored within the cytoplasm as ferritin. Administration of recombinant human erythropoietin induces changes in iron metabolism, which are reflected by decreases in both the serum iron level and transferrin saturation. These reductions can be marked, even in healthy individuals, and can occur in the presence of normal or even increased iron stores.

Published
1996

47. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

Author

Eschbach, Joseph W., Kelly, Michael R., Haley, Rebecca, Abels, Robert I., and Adamson, John W.

Subjects
Erythropoietin -- Evaluation, Anemia -- Care and treatment, Chronic kidney failure -- Complications
Abstract

Seventeen patients with kidney failure, with a shortage of red cells in the blood (anemia), and who did not yet require use of an artificial kidney machine (dialysis) were studied to determine the effects of erythropoietin, a hormone produced in the kidneys that simulates red blood cell production. The erythropoietin doses were adjusted according to resulting levels of red cells in the blood, and ranged between 50 and 150 units per kilogram of body weight. In all patients, erythropoietin promoted the production of red cells. The rate of response depended on the initial erythropoietin dose, and was similar to that observed in patients on dialysis. Fourteen patients had high blood pressure before treatment, and two developed it during treatment; high blood pressure worsened during treatment in nine, who needed medication to fight it. The rate of deterioration in kidney function did not change significantly as the volume of red blood cells rose during treatment. All patients reported an improved appetite, activity level, and sense of well-being. Erythropoietin is considered an effective treatment for correcting anemia in kidney-failure patients without disturbing remaining kidney function, although it may be associated with an increase in blood pressure.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results